Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.4.3 (phospholipase C)
 18,461 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In isolated pancreatic islets of rats, exogenous phospholipase A2 produced concentration-dependent insulin secretion. p-Bromophenacyl bromide-treated enzyme no longer showed the insulinotropic effect. The insulinotropic effect of phospholipase A2 was inhibited by nordihydroguaiaretic acid (NDGA) and 1-phenyl-3-pyrazolidinone (Phenidone) but not by indomethacin. Exogenous phospholipase C also demonstrated a concentration-related insulinotropic effect. The phospholipase C-induced insulin secretion, however, was inhibited by none of the above inhibitors. These results indicate that a lipoxygenase product(s) is involved in the insulinotropic action of phospholipase A2.
 ...
PMID:Insulinotropic effects of exogenous phospholipase A2 and C in isolated pancreatic islets. 681 52

Mepacrine and p-bromophenacyl bromide, in addition to their inhibitory effect on lipolysis, are also potent inhibitors of fatty acid acylation into renal medullary lipids. Significant qualitative and quantitative differences in the inhibition by the two drugs were seen. p-Bromophenacyl bromide exerted a non-selective effect inhibiting the incorporation of saturated and unsaturated fatty acids into all phospholipid classes and triacylglycerols. In contrast, mepacrine selectively inhibited the incorporation of both saturated and unsaturated acids into phosphatidylcholine, phosphatidylethanolamine and triglycerides, and concurrently markedly enhanced their incorporation into phosphatidylinositol. Quantitative analysis of these mepacrine effects, together with the known inhibitory effects of this compound on phospholipase A2 and phosphatidylinositol-specific phospholipase C, suggests that mepacrine also inhibits phosphatidic acid phosphatase, thereby shunting the flux of phosphatidic acid away from diglyceride formation and into synthesis of phosphatidylinositol.
 ...
PMID:Phospholipase A2 inhibitors. Differential inhibition of fatty acid acylation into kidney lipids by mepacrine and p-bromophenacyl bromide. 687 Sep 35